These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 15160318

  • 1. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
    Rosenoff S.
    Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
    [Abstract] [Full Text] [Related]

  • 2. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy.
    Rosenoff SH.
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):380-3. PubMed ID: 15305907
    [Abstract] [Full Text] [Related]

  • 3. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
    Mystakidou K, Katsouda E, Tsilika E, Smyrniotis V, Vassiliou I, Tsiatas M, Vlahos L.
    Anticancer Res; 2006 Sep; 26(3B):2325-8. PubMed ID: 16821610
    [Abstract] [Full Text] [Related]

  • 4. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L.
    J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
    Hoff PM, Saragiotto DF, Barrios CH, del Giglio A, Coutinho AK, Andrade AC, Dutra C, Forones NM, Correa M, Portella Mdo S, Passos VQ, Chinen RN, van Eyll B.
    J Clin Oncol; 2014 Apr 01; 32(10):1006-11. PubMed ID: 24516038
    [Abstract] [Full Text] [Related]

  • 6. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
    Topkan E, Karaoglu A.
    Oncology; 2006 Apr 01; 71(5-6):354-60. PubMed ID: 17873499
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article.
    Bhattacharya S, Vijayasekar C, Worlding J, Mathew G.
    Acta Gastroenterol Belg; 2009 Apr 01; 72(3):289-95. PubMed ID: 19902860
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun 01; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review.
    Deng C, Deng B, Jia L, Tan H.
    BMJ Open; 2017 Jun 21; 7(6):e014916. PubMed ID: 28637728
    [Abstract] [Full Text] [Related]

  • 12. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.
    Gebbia V, Carreca I, Testa A, Valenza R, Curto G, Cannata G, Borsellino N, Latteri MA, Cipolla C, Florena M.
    Anticancer Drugs; 1993 Aug 21; 4(4):443-5. PubMed ID: 8400346
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Successful use of long-acting octreotide for intractable chronic gastrointestinal bleeding in children.
    O'Meara M, Cicalese MP, Bordugo A, Ambrosi A, Hadzic N, Mieli-Vergani G.
    J Pediatr Gastroenterol Nutr; 2015 Jan 21; 60(1):48-53. PubMed ID: 25162361
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE, Thornton-Jones VA, Wass JA.
    Clin Endocrinol (Oxf); 2004 Aug 21; 61(2):224-31. PubMed ID: 15272918
    [Abstract] [Full Text] [Related]

  • 20. Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial.
    Garcia Compean D, Ramos Jimenez J, Guzman de la Garza F, Saenz C, Maldonado H, Barragan RF, Michel H.
    AIDS; 1994 Nov 21; 8(11):1563-7. PubMed ID: 7848592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.